Spotlight
 |
Announcing the International launch of Abbott Vascular's flagship drug
eluting stent system, the XIENCE V Everolimus
Eluting Coronary Stent System.* *CAUTION: XIENCE V is an investigational device. Limited by Federal (U.S.) law to investigational use only. |
|
|
|
 |
10,000+ Reasons to Believe Abbott Vascular exceeds 10,000 patient enrollments across its Carotid Artery Stenting (CAS) trials. |
|
|
|
 |
Reimbursement Resource Keep up with the latest information on coverage, coding and payment for coronary, carotid and other peripheral procedures related to Abbott Vascular devices. |
|
|
|
Investors & Media
- Study in JAMA Shows Patients Treated with Abbott's XIENCE™ V Drug Eluting Stent Experience Better Outcomes than Patients Treated with Market-Leading Drug Eluting Stent
- Abbott's XIENCE™ V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
- The Lancet Publishes Results from World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Abbott Receives CE Mark for Smaller-Size XIENCE™ V Drug Eluting Stent
- Abbott Gains Reimbursement for XIENCE V Drug Eluting Stent in France
- Abbott to Initiate First Study to Evaluate XIENCE™ V Everolimus Eluting Coronary Stent System in Treatment of Women with Cardiovascular Disease
LT2922560 Rev AM